|Bid||43.89 x 100|
|Ask||43.93 x 300|
|Day's range||43.43 - 44.00|
|52-week range||25.67 - 46.51|
|PE ratio (TTM)||39.86|
|Earnings date||26 Feb 2018 - 2 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||45.33|
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2017. The company anticipates fourth quarter 2017 sales of approximately $175.5 million, an increase of 15.8% over the fourth quarter 2016. Full year 2017 estimated sales are expected to be approximately $635.4 million, an increase of 12.7% over the prior year.
A new spine surgery robot has arrived on the scene to challenge Mazor's current dominance.
Globus Medical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Globus Medical (GMED) saw its shares rise nearly 8% on the day after the company reported year-over-year growth in third-quarter earnings and revenues.
Globus Medical (GMED) reports in-line third-quarter numbers on the back of higher revenues from core international business.
The musculoskeletal-implant maker eyes its new Excelsius GPS robotic surgical system for future growth.
On a per-share basis, the Audubon, Pennsylvania-based company said it had profit of 26 cents. Earnings, adjusted for one-time gains and costs, came to 30 cents per share. The results met Wall Street expectations. ...